[Multiple myeloma].
Multiple myeloma causes debilitating clinical symptoms including intractable bone pain, disabling multiple fractures and hypercalcemia. Bisphosphonates, potent inhibitors of osteoclast-mediated bone destruction, prevent skeletal-related events in myeloma. However, the impact of long-term bisphosphonate use remains unclear because of insufficient follow-up, while osteonecrosis of the jaw (ONJ) emerges as a major concern. The proteosome inhibitor bortezomib is a novel anti-myeloma agent, which has been recently drawn a considerable attention in its anabolic effects to resume bone formation in patients with myeloma. It is important to clarify the roles of these bone-targeting agents in the treatment for a myeloma bone disease and make the best use of them by eliminating underlying risk of their adverse effects.